"Glenmark Pharmaceuticals Inc, USA has been granted final approval by the US Food and Drug Administration (USFDA) for Potassium Chloride Extended Release Tablets USP, 10mEq (750 mg) and 20mEq (1500mg)," it said in a BSE filing.
According to IMS MAT September 2015 sales data, Potassium Chloride extended release capsules had US sales of USD 85.6 million.